Alternatives to Isomorphic Labs

Recursion OS pairs automated wet labs with AI models for AI drug discovery at up to 2 million weekly experiments.

Generative AI drug discovery suite spanning target ID, molecule design, biologics and clinical trial prediction.

AI-native pharma company using autonomous agents to find new uses for existing drugs and predict patient drug response

Nimbus Therapeutics designs highly selective small-molecule drugs for oncology, immunology, and metabolic disease.

Physics-based molecular simulation with AI for drug discovery and materials design.

Xaira Therapeutics pairs causal AI perturbation models X-Cell and X-Design with agentic and robotic labs to find, design, and validate new

Open-source, self-hosted AI research assistant for drug discovery — molecular property prediction, virtual screening and PK/PD modeling on your own hardware.

Owkin's K Pro is an autonomous AI scientist agent for biopharma R&D, turning multimodal patient data into drug discovery and clinical trial

Evotec is a life-science partner running AI-assisted drug discovery and Just–Evotec Biologics manufacturing.

Atomwise APEX Protocol screens 10 billion compounds in under 30 seconds for small-molecule drug discovery

Generate Biomedicines uses generative biology to design AI protein therapeutics — antibodies, enzymes, and cytokines — and move them into

All-in-human AI foundation models for precision neurology — vBx-1.0 predicts brain activity and therapy response from a blood draw.

Iktos pairs generative AI with robotic lab automation to compress small-molecule drug discovery.

Iambic Therapeutics pairs Enchant v3 and NeuralPLexer AI drug discovery with weekly wet lab readouts and a clinical-stage pipeline.

Causal AI drug discovery pairing 20+ petabytes of cellular data with human genetics to find true disease targets

BenevolentAI applies a decade-built biomedical knowledge graph to drug target discovery and repurposing for biopharma R&D teams.

Recursion runs AI drug discovery as a lab-in-the-loop engine — automated cellular imaging at scale feeding generative chemistry and a clinical pipeline.

AI drug discovery engine pairing 2M weekly automated lab experiments with a 50+ PB proprietary dataset.

Silico is Goodfire's interpretability agent for understanding and debugging the internals of your AI models.

FDA-cleared AI for cancer pathology: prostate, breast, GI and pan-cancer detection on H&E slides, plus Virchow foundation models for research.

PathAI delivers FDA-cleared AISight Dx digital pathology and AI biomarker algorithms for labs and biopharma trials.

AI-first biotech pairing Proton's machine-learning medicinal chemistry with synthesis-aware molecule design.

SciSpace BioMed Agent runs multi-omics, variant prioritization, and drug repurposing analysis from plain-language biomedical prompts.

WhiteLab Genomics' ALFRED platform predicts and optimizes molecular constructs for gene and RNA therapies before synthesis

AI-CRISPR target discovery platform pairing AlgenCRISPR gene modulation with the AlgenBrain foundation model for causal immunology and

Project-based AI biopharma team that delivers decision-grade research, analysis, and computational design in 3–5 days.

DNABERT is an open-source BERT-style transformer pre-trained on the human genome for DNA sequence prediction.

AI enzyme design for pharma manufacturing and life science tools, validated in Pando's own ultra-high-throughput screening lab.

Haplotype Labs builds SaaS and community tooling for population genetics, aiming to cut sequencing costs 50–90% and speed polygenic risk modeling.

Nanograb designs peptide-LNP targeting systems with biophysics-informed AI so genetic medicines reach a chosen cell type instead of the liver.